Topping out of GenScript Life Science Reagent R&D and Manufacturing Building Fuels High-quality Growth of Biopharmaceutical Services

On October 18, Nanjing GenScript announced topping out of its life science reagent R&D and manufacturing building. Upon completion, the project will be a great addition to domestic and international biopharmaceutical R&D outsourcing services by upgrading R&D and manufacturing capabilities.

Topping out of the structure

The project was initiated in April 2022 with total funding of RMB 1 billion. The building will cover a floor area of 10,000 m2 and a building area of 30,200 m2. Following phase I project, a high caliber facility and central warehouse will be operational to address research and manufacturing needs. Despite the impact of the COVID pandemic, GenScript finished topping out in six months as planned with epidemic prevention and work safety measures in place.

GenScript's life science reagent R&D and manufacturing building is designed as an integrated life science R&D service platform, which will leverage new technology to drive transformation and upgrading of manufacturing into services. In recent years, innovative biologics has been one of the fastest-growing segment in the pharmaceutical industry, attracting a number of biopharmaceutical players. This project will maximize the capabilities of leading biopharmaceutical enterprises, fuel high-quality growth across the industry chain, and bring affordable innovative biologics to patients.

Rendering of the building

In recent years, GenScript has made significant investment in infrastructure to meet the needs of over 200,000 global customers. Since 2021, GenScript has worked on capacity expansion in the US, Singapore and China and ramp-up of projects in peptide, sgRNA, ssDNA and GMP beads. Many believe that this building will facilitate GenScript to synergize upstream and downstream services from life science reagent services in gene, peptide, protein, and antibody to biologics development, provide high-quality one-stop CRO and CMO services, significantly shorten the product development cycle, and grab more market share in the global biopharmaceutical market.

About GenScript Biotech Corporation

GenScript Biotech Corporation (HK.1548) is the world’s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform and the industrial synthesis biological product platform.

GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland. GenScript Biotech provides premium, convenient and reliable services and products for over 200,000 customers.

As of June 30, 2022, GenScript Biotech had more than 5,500 employees globally, over 38% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript Biotech owns a number of intellectual property rights, including over 190 patents, over 820 pending patent applications and great numbers of trade secrets.

Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript Biotech strives to become the most trustworthy biotech company in the world. As of June 30, 2022, 74,700 peer-reviewed journal articles worldwide have cited GenScript Biotech’s services and products.

For more information, please visit GenScript Biotech's official website

https://www.genscript.com

For More Information Contact